Gelderblom H - Search Results

1

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.

Steeghs N, Mathijssen RH, Wessels JA, de Graan AJ, van der Straaten T, Mariani M, Laffranchi B, Comis S, de Jonge MJ, Gelderblom H, Guchelaar HJ. Steeghs N, et al. Among authors: gelderblom h. Invest New Drugs. 2011 Oct;29(5):953-62. doi: 10.1007/s10637-010-9405-7. Epub 2010 Feb 25. Invest New Drugs. 2011. PMID: 20182906 Free PMC article. Clinical Trial.

2

Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans.

Loos WJ, Verweij J, Gelderblom HJ, de Jonge MJ, Brouwer E, Dallaire BK, Sparreboom A. Loos WJ, et al. Among authors: gelderblom hj. Anticancer Drugs. 1999 Sep;10(8):705-10. doi: 10.1097/00001813-199909000-00003. Anticancer Drugs. 1999. PMID: 10573202 Clinical Trial.

3

Topotecan lacks third space sequestration.

Gelderblom H, Loos WJ, Verweij J, de Jonge MJ, Sparreboom A. Gelderblom H, et al. Clin Cancer Res. 2000 Apr;6(4):1288-92. Clin Cancer Res. 2000. PMID: 10778953 Clinical Trial.

4

Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.

Loos WJ, Gelderblom H, Sparreboom A, Verweij J, de Jonge MJ. Loos WJ, et al. Among authors: gelderblom h. Clin Cancer Res. 2000 Jul;6(7):2685-9. Clin Cancer Res. 2000. PMID: 10914710

5

Gender-dependent pharmacokinetics of topotecan in adult patients.

Loos WJ, Gelderblom HJ, Verweij J, Brouwer E, de Jonge MJ, Sparreboom A. Loos WJ, et al. Among authors: gelderblom hj. Anticancer Drugs. 2000 Oct;11(9):673-80. doi: 10.1097/00001813-200010000-00001. Anticancer Drugs. 2000. PMID: 11129727 Clinical Trial.

6

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer.

Gelderblom H, Sparreboom A, de Jonge MJ, Loos WJ, Wilms E, Mantel MA, Hennis B, Camlett I, Verweij J, van der Burg ME. Gelderblom H, et al. Br J Cancer. 2001 Oct 19;85(8):1124-9. doi: 10.1054/bjoc.2001.2014. Br J Cancer. 2001. PMID: 11710824 Free PMC article. Clinical Trial.

7

Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.

Gelderblom H, Loos WJ, Verweij J, van der Burg ME, de Jonge MJ, Brouwer E, Nooter K, Stoter G, Sparreboom A. Gelderblom H, et al. Eur J Cancer. 2002 Jan;38(1):205-13. doi: 10.1016/s0959-8049(01)00348-3. Eur J Cancer. 2002. PMID: 11750851

8

Influence of the cisplatin hydration schedule on topotecan pharmacokinetics.

Gelderblom H, Loos WJ, Sparreboom A, Soepenberg O, de Jonge MJ, van Boven-van Zomeren DM, Verweij J. Gelderblom H, et al. Eur J Cancer. 2003 Jul;39(11):1542-6. doi: 10.1016/s0959-8049(03)00316-2. Eur J Cancer. 2003. PMID: 12855260

9

Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.

Gelderblom H, Salazar R, Verweij J, Pentheroudakis G, de Jonge MJ, Devlin M, van Hooije C, Seguy F, Obach R, Pruñonosa J, Principe P, Twelves C. Gelderblom H, et al. Clin Cancer Res. 2003 Sep 15;9(11):4101-7. Clin Cancer Res. 2003. PMID: 14519632 Clinical Trial.

10

Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.

van Erp NP, Baker SD, Zhao M, Rudek MA, Guchelaar HJ, Nortier JW, Sparreboom A, Gelderblom H. van Erp NP, et al. Among authors: gelderblom h. Clin Cancer Res. 2005 Nov 1;11(21):7800-6. doi: 10.1158/1078-0432.CCR-05-1288. Clin Cancer Res. 2005. PMID: 16278402

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

851 results

Search Page